WO2001064930A1 - Nanoparticules creuses proteiques, transporteur associe a l'utilisation de ces nanoparticules et procede d'introduction d'une substance dans des cellules - Google Patents
Nanoparticules creuses proteiques, transporteur associe a l'utilisation de ces nanoparticules et procede d'introduction d'une substance dans des cellules Download PDFInfo
- Publication number
- WO2001064930A1 WO2001064930A1 PCT/JP2001/000926 JP0100926W WO0164930A1 WO 2001064930 A1 WO2001064930 A1 WO 2001064930A1 JP 0100926 W JP0100926 W JP 0100926W WO 0164930 A1 WO0164930 A1 WO 0164930A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- cell
- hbsag
- particles
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the invention of this application relates to hollow nanoparticles in which a biorecognition molecule is introduced into a protein capable of forming particles. More specifically, the invention of this application relates to hollow nanoparticles that can be used as a carrier for introducing a substance into specific cells and tissues. Background art
- DDS drug delivery system
- the ribosome method is known as a highly safe substance introduction method. Since this method does not damage cells, it can be applied to cells and tissues inside a living body. However, it is difficult to impart a high degree of cell and tissue specificity to the simple lipid ribosome, and the gene transfer rate at / 7 is much lower than required. There's a problem.
- the invention of this application has been made in view of the circumstances as described above, and solves the problems of the prior art, and adds substances (genes, proteins, compounds, etc.) to target cells and tissues.
- Specific and safe The task is to provide a general-purpose method for transportation and introduction. Disclosure of the invention
- the invention provides hollow nanoparticles characterized in that a biorecognition molecule is introduced into a protein having a particle-forming ability. I do.
- the invention of this application provides hollow nanoparticles characterized in that biorecognition molecules are introduced into protein particles obtained by expressing proteins in eukaryotic cells.
- the invention of the present application is characterized in that the eukaryotic cell is selected from either yeast or transgenic yeast, and fourthly, that the eukaryotic cell is an insect cell.
- the invention is provided as an embodiment of the hollow nanoparticles of the invention.
- the invention of this application provides any of the above empty nanoparticles, wherein the protein forming the particles is a hepatitis B virus surface antigen protein.
- the invention of the present application provides the hollow nanoparticle, wherein the hepatitis B virus surface antigen protein is a hepatitis B virus surface antigen protein having reduced antigenicity. I do.
- the biorecognition molecule is a cell function regulating molecule
- the biorecognition molecule is an antigen
- the biorecognition molecule is a sugar chain, which is provided as an embodiment of any of the hollow nanoparticles described above.
- the invention of the present application further includes any one of the hollow hollow tubes described above. Also provided is a substance carrier characterized in that a cell-introduced substance is included in the nanoparticles.
- the invention of the present application is also directed to the substance carrier according to the eleventh aspect, wherein the second is that the cell-introducing substance is a gene, and the thirteenth is that the cell-introducing substance is a protein.
- the cell-introducing substance is an RNase showing cytotoxicity in cells, and a fifteenth aspect provides that the cell-introducing substance is a compound.
- the invention of this application is directed to a method for manufacturing the substance carrier according to any one of the above-mentioned first to fifteenth inventions.
- Either one of the hollow nanoparticles contains a cell-introduced substance by an electroporation method
- the first part contains a cell-introduced substance by an ultrasonic method
- the present invention provides that a cell-introduced substance is encapsulated by the simple diffusion method.
- the invention of the present application provides a method for introducing a substance into a cell or tissue, which comprises using the hollow nanoparticles of any one of the first to tenth aspects.
- 1 provides a method for introducing a substance into a cell or tissue, which comprises using the substance carrier according to any one of the first to the fifteenth.
- the invention of this application also provides a method for treating a disease that includes an operation of transporting a substance to a specific cell or tissue using at least one of the substance introduction methods described above. I do. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 is a schematic diagram showing each protein region of the HBsAg gene in an example of the present invention. 1 to 8 represent each of the surface antigens The function of the part is shown. (1: Suppression of release, 2: Receptor, 3: Sugar chain 1, 4: Serum polymerized albumin receptor, 5: Transmembrane, 6: Stabilization, 7: Sugar chain 2, 8: Transmembrane low polymerization ⁇ secretion)
- FIG. 2 is a schematic explanatory view illustrating the operation of expressing and purifying HBsAg particles using the recombinant yeast in Examples of the present invention.
- FIG. 3 is a fluorescence micrograph of a confocal point laser of HepG2 when HBsAg particles introduced with GFP plasmid and HepG2 were brought into contact with each other in the example of the present invention.
- Fig. 4 is a confocal laser fluorescence micrograph showing that GFP-encapsulated HBsAg particles express GFP in human liver cancer-derived cells (NUE) to the same extent as HepG2.
- FIG. 5 is a diagram showing a confocal laser fluorescence micrograph showing that HBsAg particles can extremely specifically introduce GFP into human liver cancer-derived cells (HuH-7).
- A Tumor of a bile cancer mouse transplanted with human liver cancer-derived cells (HuH-F) (fluorescence);
- HuH-F human liver cancer-derived cells
- HuH-F normal liver of mouse
- the hollow nanoparticles of the invention of this application are proteins having a particle forming ability.
- a biorecognition molecule By introducing a biorecognition molecule into a substance, it is possible to transport a substance specifically to a target cell or target tissue.
- subviral particles obtained from various viruses can be applied. Specifically, hepatitis B virus (HBV) surface antigen protein is exemplified.
- HBV hepatitis B virus
- examples of protein particles composed of a protein having such particle forming ability include those obtained by expressing a protein in eukaryotic cells.
- a protein capable of forming particles when expressed in eukaryotic cells, the protein is expressed as a membrane protein on the endoplasmic reticulum membrane, accumulated, and released as particles. is there.
- yeast, genetically modified yeast, insect cells, and the like can be used as eukaryotic cells.
- the present inventors express the above-mentioned HBV surface antigen L protein in a genetically modified yeast, thereby obtaining yeast-derived lipids from the expressed HBV surface antigen L protein.
- elliptical hollow particles with a minor axis of about 20 nm and a major axis of about 150 nm are formed in which a large number of the same proteins are embedded in a bilayer membrane. Bio. Chem., Vo I. 267, No. 3, 1953-1961, 1992). Since such particles do not contain any HBV genome / HBV proteins, they do not function as viruses and are extremely safe for the human body.
- hepatocyte-specific receptors responsible for the extremely high infectivity of HBV to hepatocytes are displayed on the particle surface, the effect as a carrier that specifically transports substances to hepatocytes is exhibited. Is also expensive.
- the method of forming protein particles using genetically modified yeast produces particles with high efficiency from soluble proteins in the cells. It is suitable in this respect.
- insect cells are eukaryotic cells that are closer to higher animals than yeast, but are capable of reproducing higher-order structures such as sugar chains that yeast cannot reproduce.
- the conventional insect cell system used a baculovirus and involved the expression of the virus. Therefore, when the protein was expressed, the cells died and were lysed. As a result, there has been a problem that the protein is continuously expressed or the protein is degraded by a protease released from dead cells. In addition, when the protein was expressed by secretion, a large amount of fetal calf serum contained in the medium was mixed, so that purification was difficult even if the protein was secreted into the medium.
- a baculovirus-free insect cell system capable of serum-free culture has been developed and marketed by Invitrogen. Therefore, by using such insect cells, protein particles that can be easily purified and reproduce a higher-order structure can be obtained.
- the receptor on the particle surface obtained by the above-described various methods can be modified into any biorecognition molecule, or various substances (DNA, RNA, protein, By introducing peptides and drugs into the particles, it becomes possible to transport and introduce substances with extremely high specificity to any cells and tissues other than hepatocytes.
- the protein having the particle shape performance is not limited to the above-mentioned hepatitis B virus surface antigen protein, but any protein capable of forming particles.
- natural proteins derived from animal cells, plant cells, viruses, fungi, and the like, various synthetic proteins, and the like are also considered.
- Biorecognition molecules to be introduced into proteins capable of forming particles include, for example, cells and regulatory molecules such as growth factors and cytokines, cells and antigens such as cell surface antigens, tissue-specific antigens, and receptors.
- cells and regulatory molecules such as growth factors and cytokines
- cells and antigens such as cell surface antigens, tissue-specific antigens, and receptors.
- molecules derived from viruses and microorganisms, antibodies, sugar chains, lipids and the like are preferably used. These are appropriately selected depending on the target cell or tissue.
- a substance carrier having cell specificity can be obtained by encapsulating a substance (cell-introduced substance) to be introduced into a target cell or tissue into the protein hollow nanoparticles as described above.
- the cell-introduced substance contained in the substance carrier is, for example, a gene such as DNA or RNA, a natural or synthetic protein, an oligonucleotide, a peptide, a drug, a natural or synthetic compound, or the like. Is also good.
- cytoplasmic carrier enables the forced expression of a protein having cytotoxic activity selectively in cells and tissues, and is expected as a new cancer treatment method.
- a method for introducing these cell-introduced substances into the hollow nanoparticles various methods used in ordinary chemical and molecular biological experimental techniques are applied.
- preferred examples include an electoral-portation method, an ultrasonic method, a simple diffusion method, and a method using a charged lipid.
- the introduction of a substance into specific cells or tissues using the above-described protein hollow nanoparticles and substance carriers is a treatment for various diseases. It can also be done as a step in the law or treatment.
- HBsAg does not mean Hepatitis B virus surface Hepatit is Birus surface Antigen.
- HBsAg is an envelope protein of HBV.
- S protein is common to the three proteins This is an important coat protein
- M protein is the S protein with 55 amino acids (pre-S2 peptide) added to the N-terminal side of the S protein.
- the L protein is obtained by adding 108 or 119 amino acids (pre-S1 peptide) to the N-terminal side of the M protein.
- Pre-S regions (pre-S1, pre-S2) of the HBsAgL protein play important roles when HBV binds to hepatocytes.
- Pre-SI has a site that directly binds to hepatocytes
- pre-S2 has a polymerized albumin receptor that binds to hepatocytes via polymerized albumin in the blood.
- HBsAg When HBsAg is expressed in eukaryotic cells, the protein is expressed and accumulated as a membrane protein on the endoplasmic reticulum membrane.
- the L protein of HBsAg undergoes intermolecular aggregation and is released as particles to the rumen side in a budding manner while taking up the endoplasmic reticulum membrane.
- FIG. 2 shows a schematic explanatory diagram of the expression and purification procedures of HBsAg particles described in the following Examples.
- HBsAg was a protein having a molecular weight of about 52 kDa.
- HBsAg was a protein having a molecular weight of 52 kDa and having S antigenicity.
- about 24 mg of purified HBsAg particles were obtained from 26 g of wet cells derived from 2.5 L of the culture medium.
- yeast-derived protease was completely removed in a series of purification steps.
- Sea urchin I made the index Oh Ru human Bok in growth phase liver cancer cells H ep G 2 to 1 X 1 0 5 ce II s / we II, was inoculated to 3. 5 cm glass bottom dishes petri dish, 3 full ° C, 5 The cells were cultured overnight in the presence of 10% CO 2 using D-MEM containing 10% fetal serum. The next day, HBsAg particles were mixed with green fluorescent protein expression plasmid (GFP expression piasm id pTB701-hGFP), and the mixture was subjected to electrification.This sample was mixed with the HepG2 culture solution. And 3 7 C, and cultured for 4 days in 5% C_ ⁇ 2 presence.
- GFP expression piasm id pTB701-hGFP green fluorescent protein expression plasmid
- FIG. 3 shows a confocal laser photograph of Hep G2. Comparing Fig. 3 (a) with Figs. 3 (b) and (c), Fig. 3 (a) shows about 200 times the efficiency of Fig. 3 (b), indicating that GFP by HBsAg particles The introduction efficiency of express ion p I asm id was found to be very high.
- human liver cancer-derived cells were prepared from HuH-F (JCRB0403) and NUE (provisioned by Professor Takashi Takumakuma, Department of Parasitology, National Defense Medical College).
- human colon cancer-derived cells W i Dr (ATCC CCL-218), HT29 (ATCC HTB-38), SW 11 16 (ATCC CCL-233), human malignant cells Melanoma-derived cells SEKI (JCRB0620) and human squamous cell carcinoma-derived cells A431 (JC B9009) were cultured on 3.5 cm glass bottom dishes, each containing GFP-expressing plasmid (pEGFP).
- pEGFP GFP-expressing plasmid
- -F C lontech Co.
- the HBsAg particles of the present invention were thus, it was shown that genes can be introduced into human hepatocytes with extremely high specificity and efficiency.
- Bile carcinoma mice were subcutaneously subcutaneous on both sides of nude mice (strain: BALB / c nu / nu, microbiological quality: SPF, gender: os 5 weeks old). injected H u H- 7 and W i D r) to 1 x 1 0 7 cells subcutaneously respectively, transplanted tumor was obtained by 2 grown 6 weeks until the solid cancer having a diameter of about 2 cm.
- HBsAg particles 10; ug containing GFP expression plasmid (pEGFP-F) 2 obtained by the method described in Example 2 were injected intraperitoneally into a mouse using a 26G injection needle.
- pEGFP-F GFP expression plasmid
- Sections were prepared according to a standard method, stained with hematoxylin (general tissue staining) at the same time, and the GFP fluorescence of the HBsAg particle-treated group and the non-treated group was compared with a fluorescence microscope (Fig. 5 ).
- fluorescence derived from GFP was observed in the tumor part of the bile cancer mouse due to human liver cancer-derived HuH-7 cells.
- no fluorescence was observed in the liver, spleen, kidney, and intestinal tract that were simultaneously removed from the mouse.
- No fluorescence was observed in the tumor, liver, spleen, kidney, intestinal tract, or non-HBsAg particle-administered group of bile cancer mice due to human colon cancer-derived W ⁇ Dr cells. From the above, it was shown that the use of HBsAg particles enables gene transfer to human hepatocytes with extremely high specificity and efficiency even at the experimental animal level. Therefore, it was confirmed that the substance carrier of the present invention was extremely effective.
- HB s A g particles can infect human hepatocyte-specific, hepatocyte recognition site is presented in the surface of the particles responsible for its high infectivity, 3 to 7 7 amino of P Re_S1 region Ec> eyec J, Chouteau P, Cannè e I, Guguen-Gui I louzo C, Gripon P., J. Virol 1999, Mar; 73 (3): 2052—7).
- modified HBsAg particles capable of retaining high particle infectivity for hepatocytes while maintaining the particle-forming ability of HBsAg particles, and capable of displaying any biorecognition molecule on the particle surface (Hereinafter referred to as HBsAg-NuII particles).
- Pfu DNA polymerase (Stratagene) was used as the heat-resistant DNA polymerase, and the PCR schedule was set at 95 ° C. Denaturation for 30 seconds, annealing at 55 ° C for 1 minute, and synthesis reaction at 68 ° C for 30 minutes were repeated 30 times. Then, the PCR product is treated with restriction enzyme I, transformed into Escherichia coli DH5 ⁇ , vector DNA is extracted from the emerging colonies, and p GLDLII ⁇ 39 — R c T Plasmid was selected. (Hereafter referred to as pGLDLIIP39-RcT (nuII)).
- pGLDLIIP39-RcT (nuII) plasmid was transformed, cultured in a synthetic medium High-Pi and 8S5N-P400, and HBsAg-NuII. The particles were developed.
- a crude extract of the cells is prepared using the recombinant yeast yeast ⁇ b (Yeast Protein Extraction Reagent Pierce Chemical Co., Ltd.) in the stationary growth phase (two hours after the start of culture), and separated by SDS-PAGE. After separation, HBsAg-NuII was identified by silver staining and Western method using an anti-S monoclonal antibody (Funakoshi).
- HBsAg—NulI was a protein having a molecular weight of about 42 kDa.
- Example 4 Gene Transfer Using HBsAg—NulI Particles in Human-Derived Cancer Cells
- Example 2 the high infectivity for hepatocytes obtained in Example C is deleted, and any biorecognition molecule is attached to the particle surface.
- a plasmid for expressing GFP pEGFP-F (Clontech)
- pEGFP-F Cellular fibroblasts
- HepG2 cells and various humans described in Example 2 are encapsulated.
- Gene transfer into the derived cancer cells was performed at the cultured cell level.
- a bile cancer mouse transplanted with a human tumor strain (1 "11_) 1" 1-7 and ⁇ ⁇ iDr) was prepared, and a GFP expression plasmid (pEGFP-F ( Although HBsAg-NuII particles containing Clontech) were administered, no GFP fluorescence was observed in the tumor site and in all major organs.
- pEGFP-F Although HBsAg-NuII particles containing Clontech
- the EGF receptor is expressed on an extremely large number of cells on the cell surface, and it is known that it is particularly involved in the exacerbation of certain types of cancer (esophageal cancer, colorectal cancer, etc.). Therefore, the production of HBsAg particles targeting the EGF receptor is considered to be an effective treatment for cancer tissues that express the EGF receptor.
- HBsAg-EGF particles EGF-presenting HBsAg particles
- Human-derived EGF precursor cDNA fragment Bell GI, Fong M, Stempen MM, Wormsted MA, Caput D, Ku LL, Urdea MS, Rail LB, Sanchez-Pescador R Nucleic Acids Res 1986 No 11; 14 ( 21) With the --type defined by 8427-46), a gene fragment encoding the mature human EGF region (53 amino acid residues) was amplified by the PCR method as usual.
- PCR primers used were the oligonucleotide of SEQ ID NO: 3 on the sense side and the oligonucleotide of SEQ ID NO: 4 on the antisense side, both of which were restriction enzyme Not ⁇ sites at the 5 'end. gcggccgc).
- the plasmid was named pGLDLIIP39-RcT-EGF the 3 ⁇ 4
- pGLDLIIP39-RcT-EGF plasmid was transformed and cultured in a synthetic medium, High-Pi and 8S5N-P400, to obtain HBsAg-EGF particles.
- a synthetic medium High-Pi and 8S5N-P400
- HBsAg-EGF was a protein with a molecular weight of about 50 kDa.
- HBsAg-EGF particles were obtained from the above cells (about 26 g) derived from 2.5 L of the culture medium.
- the Auszyme II El A kit (Dynabot), which can detect only the particle structure of HBsAg, S antigenicity of HBsAg particles and HBsAg-EGF particles (HBsAg g)
- the same value was observed in both cases.
- the HBsAg-EGF particles were obtained in the same manner as the HBsAg particles.
- a plasmid pEGFP-F vector (CI ontech) for expressing GFP was encapsulated inside the HBsAg-EGF particles, and described in HepG2 cells and Example 2.
- the gene transfer into the various human-derived cancer cells was performed at the cultured cell level.
- c Kitareyo Li which could be observed a strong fluorescence by GFP in A 4 3 1 cells expressing a large amount of cellular surface EGF receptor, HB s A g one EGF particles EGF receptor one expression It was confirmed to have high infectivity for cells. In addition, it was shown that the modified HBsAg particles can be given any biorecognition ability at the cultured cell level.
- Example 1 Gene Transfer Using HBsAg_EGF Particles to Nud Mice Transplanted with Human-Derived Cancer Cells
- a bile cancer mouse transplanted with a human tumor line (A431, HuH_7, WiDR) was prepared, and a GFP expression plasmid (pEGFP-F
- pEGFP-F GFP expression plasmid
- HBsAg-EGF particles containing (Clontech) When HBsAg-EGF particles containing (Clontech) were administered, strong fluorescence from GFP was observed in the tumor area due to A431.
- GFP fluorescence was not observed in the tumor site and major organs of other cells.
- HBsAg-EGF particles could specifically infect cells expressing a significant amount of the EGF receptor, and that they were not infectious to major organs.
- BTC is a member of the EGF family, but its expression site is different from that of EG.
- BTC plays an important role in the differentiation of Langerhans islet / 3 cells in the renal pancreas, which plays an important role in the glycemic control mechanism. Therefore, the production of HBsAg particles targeting the BTC receptor could be an effective means of delivering substances to tissues that express the BTC receptor. It is expected to be useful for the treatment of.
- HBsAg-BTC particles a method for producing BTC-presenting HBsAg particles (HBsAg-BTC particles) is described.
- PCR primers used were the oligonucleotides of SEQ ID NO: 5 on the sense side and the oligonucleotides of SEQ ID NO: 6 on the antisense side, both of which were restriction enzyme Not ⁇ sites at the 5 'end. ( GCggCC gc).
- the pGLDLIIP39-RcT-BTC plasmid was transformed in the same manner as in Example A, and cultured in a synthetic medium High-Pi and 8S5N-P400 to express HBsAg-BTC particles. I let it.
- a crude extract of the bacterial cells was prepared using the recombinant yeast sword ⁇ b and Yeast Protein Extraction Reagent (Pierce Chemical Byeon), and SDS-PAGE was performed.
- HBsAg — BTC by silver staining and Western method using anti-BTC polyclonal antibody (produced by Seo, Okayama Univ.) was done.
- HBsAg-BTC was a protein having a molecular weight of about 50 kDa.
- the bacterial cells (about 26 g) derived from 2.5 L of the culture medium and about 3 mg of purified HBsAg-BTC particles were obtained.
- the Auszyme II El A kit (Dynabot), which can detect only the particle structure of HBsAg, S antigenicity of HBsAg particles and HBsAg-BTC particles (HBsAg g)
- the same value was observed in both cases.
- Example 8 Gene transfer by HBsAg-BTC particles into human-derived cancer cells
- a plasmid for GFP expression (pEGFP_F (Clontech)) is encapsulated inside the HBsAg-BTC particles, and the rat spleen-derived cells expressing the BTC receptor are expressed.
- Gene transfer into human lung cancer-derived H69 cells that do not express AR42J and BTC receptor, and the various human-derived cancer cells described in Example 2 were performed at the cultured cell level.
- Example F Preparation of basic fibroblast growth factor (bFGF) display type HBsAg particles (HBsAg—bFGF particles)
- the production of HBsAg particles targeting the bFGF receptor is considered to be an effective substance delivery means for tissues expressing the bFGF receptor, and is effective in suppressing angiogenesis in tissues surrounding cancer. It can also be used for specifically guided treatments.
- the two types of PCR primers used were the oligonucleotide having the SEQ ID No. on the sense side and the oligonucleotide having the SEQ ID No. 8 on the antisense side, both having a restriction enzyme at the 5 'end and a restriction enzyme site. (Gcggccgc).
- a band (approximately 450 bp) containing the desired cDNA is recovered, and cCR2.1—TOPO is prepared using a T0P0 TA Cloning kit (Invitrogen). Vector (Invitrogen). After confirming the nucleotide sequence, the DNA fragment was cleaved with restriction enzyme ⁇ / otl, the target DNA fragment of about 450 bp was recovered, and pGLDLIIP39-Ret (nulI) was cleaved with restriction enzyme ⁇ oil. Using Escherichia coli and TaKaRa Ligation kit ver. 2 (TaKaRa tt), the E.
- the insert b FGF gene is selected those fused to match HB s A g gene reading frame, and p GLDLIIP 3 9- R c T- b FGF the plasmid I named it.
- Yeast Protein Extraction Reagent manufactured by Pierce Chemical Co., Ltd., L was used to prepare a crude extract of cells, and SDS- Separation was performed using PAGE, and HBsAg-bFGF was identified by silver staining and Western method using anti-bFGF monoclonal antibody 3H3 (Wako Pure Chemical Industries, Ltd.).
- HBsAg-bFGF was a protein having a molecular weight of about 58 kDa.
- HBsAg-bFGF particles were obtained from the above cells (about 26 g) derived from 2.5 L of the culture medium.
- HBsAg S antigenicity of HBsAg particles and HBsAg-bFGF particles (HBs The degree of particle formation of Ag) was measured, and the same value was observed in both cases.
- Example 9 Gene Transfer by HBsAg-b FGF Particles into Human-Derived Cancer Cells
- a plasmid for expressing GFP pEGFP-F (Clontech)
- pEGFP-F Cell-Derived Cancer Cells
- MDA-MB-231 Breast cancer-derived cells MDA-MB-231, b Cultured cells were introduced into A431 cells derived from human squamous cell carcinoma not expressing the FGF receptor and various human-derived cancer cells described in Example 2. Made at the level.
- the HBsAg_bFGF particles have high infectivity to cells expressing the bFGF receptor-1.
- a vector for expressing the RNase in a cell was constructed.
- the human RNase 1 gene (Seno, M., Futami, J., Kosaka, II., Seno, S. and Yamada, H. Biochim. Biophys. Acta 1218 (3), 466 -468 1994) as a type III primer with an oligonucleotide of SEQ ID NO: 9 (having /?
- the oligopeptide of SEQ ID NO: 11 (having the ⁇ site ctcgag) and the oligopeptide of SEQ ID NO: 12 ( ⁇ / ⁇ ⁇ site aagctt) ), A gene fragment (RM fragment) encoding human RNase 1 (128 amino acid residues), which does not contain a signal peptide, was amplified.
- the human ECP gene (Rosenber HF, Ackerman SJ and Tenen DG. J. Exp. Med. 170 (1), 163-176 1989) was transformed into a type III oligopeptide (SEQ ID NO: 13).
- the human ECP gene was transformed into type I and the oligopeptide of SEQ ID NO: 15 (having the T70I site ctcgag) and the oligopeptide of SEQ ID NO: 16 (Hind ⁇ II site aagctt) were obtained. ), A gene fragment (EM fragment) encoding human ECP (133 amino acid residues) not containing a signal peptide was amplified.
- the R0, RM,, and ⁇ fragments obtained by the above procedure were subcloned once into pGEM-Teasy vector (Promega), and after confirming the base sequence, fco? L and Hind ⁇
- the DNA fragment containing the above fragment was cut out by digestion with II, and recovered by agarose electrophoresis.
- an expression vector pTr i Ex-1 (Novagen) cleaved with EcoR ⁇ and Hind ⁇ II was prepared, and the above fragment was obtained using TaKaRa Ligation kit ver. 2 (TaKaRa 3 ⁇ 4). To form a ring bond.
- the obtained plasmids were named pTri ⁇ -1-RO, pTriEx-1-RM, pTriEx_1_E0 and pTriEx-1-EM.
- COS from African kidney, monkey kidney cells are seeded into each well of a 16-well plate with 1 ⁇ 10 4 cells and incubated at 37 ° C and 5% CO 2 at 10 ⁇ 10 The cells were cultured overnight using D-MEM containing fetal serum. The next day, ⁇ ⁇ - 1-RO, pTr i ⁇ -1-RM, pTr i ⁇ -1- ⁇ and pTr i ⁇ -1- ⁇ Each of the above plasmids was dispensed into 0, 0 ⁇ 2, 0.5, 1-0, 5. O ⁇ ig, and mixed vigorously with the 31 gene transfer lipid FuGene 6 (Roche). In addition, serum-free D-MEM medium supplemented with 10 ° I was added to each well.
- the RNase can be introduced cell-specifically, resulting in cytotoxic effects in cells. Is expected to be an effective disease treatment method.
- Example I Production of HBsAg particles by serum-free cultured insect cells
- the expression of HBsAg particles by the recombinant yeast described in Example A is extremely high, with about 400/0 of soluble proteins in the cells being produced as HBsAg.
- this is an efficient method for producing HBsAg particles, complicated operations as shown in Example B are required to obtain purified HBsAg particles.
- Yeast has a protein synthesis system such as the endoplasmic reticulum membrane that is suitable for expressing proteins derived from higher animals, but since it is a lower eukaryote, it has higher sugar chains and the like. It is known that the secondary structure cannot be reproduced.
- the PCR product was separated by agarose gel electrophoresis, and the target band of about 1.3 kbp was recovered.
- the pGR2.1-T0P0 I.V.
- TOPO TA Cloning kit Inv itrogen
- nv itrogen nv itrogen
- E. coli DH5 ⁇ E. coli DH5 ⁇ .
- a plasmid into which the target gene was correctly incorporated was selected, treated with ⁇ I Sac II, and separated by agarose gel electrophoresis.
- the Kpn ⁇ Sac ⁇ I fragment was recovered by agarose electrophoresis.
- the plasmid was named PITZTZV5-His-HBsAg.
- the modified HBsAg gene was extracted from the plasmids of pGLDLIIP39-RcT (nuII) described in Example C and pGLDLIIP39-RcT-EGF described in Example D.
- PIZTZV5—His and named pIZTZV5-His-nuII and pIZT / V5-His—EGF, respectively.
- the insect cells High Five strain (BTI-TN-5B1-4: Invitrogen), were gradually transformed from a medium containing fetal calf serum to a serum-free medium (Ultimate Insect i> erum-Free Medium) over about one month. : Invitrogen).
- PITZ / V5-His_HBsAg was transformed into a High Five strain adapted to a serum-free medium using a lipid for gene transfer, Insectin-Plus (Invitrogen).
- the cells were cultured in a serum-free medium at 27 ° C for 48 hours, and further cultured in a serum-free medium containing 400 g / mL of the antibiotic zeocin (Invitrogen) for 4 to 7 days until the cells became confluent.
- a serum-free medium containing 400 g / mL of the antibiotic zeocin (Invitrogen) for 4 to 7 days until the cells became confluent.
- the culture supernatant was collected by centrifugation at 1500 X g for 5 minutes, and the expression of HBsAg particles in the medium was measured using an Auszymel El A kit (Dynabot). It was confirmed that Ag particles were expressed.
- HBsAg particles elicit anti-HBsAg antibodies in inoculated humans. could happen. Therefore, modified HBsAg particles were prepared in which the antigenicity of S protein, which is the main antigen inside the HBsAg particles, was reduced.
- HBsAg particles a mutant form of HB virus isolated from a patient who developed hepatitis B while being an HB vaccinated person (Carman WF, Zanetti AR, Karay Iann Isp, Waters J, Manz ⁇ II o G, Tanz i E, Otsu uckerman AJ, Thomas HC; Lancet 1990 Aug 11; 336 (8711): 325-9; Ghi ou HL, Lee TS, uo J, Mau YC, Ho MS J Gen Virol 1997 Oct; 78 (Pt 10): 2639-45) was introduced into HBsAg particles.
- thermostable DNA polymerase (Stratagene) was used as the thermostable DNA polymerase, and the PCR schedule was denaturation at 95 ° C for 30 seconds, 55 ° C. Annealing for 1 minute at C and synthesis reaction at 68 ° C for 30 minutes were repeated 30 times. Thereafter, the PCR product was treated with restriction enzyme / 7 P / 7 I, was transformed into E. coli DH 5 alpha, appeared colonies extracts Karabe Kuta one DNA, p GLDLIIP 3 was mutated nucleotide sequence 9 — R c T plasmid was selected. (Hereafter referred to as pGLDLIIP39-RcT (G145R).)
- p GLDLIIP 39-R c T (G 1 4 5R) plasmid was transformed and cultured in synthetic medium High-Pi and 8S5N-P400 to express HBsAg (G145R) particles.
- HBsAg G145R was identified by silver staining and Western method using an anti-S monoclonal antibody (Funakoshi).
- HBsAg (G145R) was a protein having a molecular weight of about 52 kDa.
- HBsAg particles Approximately 20 mg of purified HBsAg (G145R) particles were obtained from 26 g). Using an Auszyme II EIA kit (Dynabot), which can detect only the particle structure based on the S antigenicity of HBsAg, HBsAg particles and HBsAg (G145 R) The S antigenicity of the particles was determined to be 0.2 for the former and 0.2 for the latter.
- P GLDLIIP 39 -R c T (G145R) In order to replace the 129th Gin residue in the S protein part of the plasmid with a co-Arg residue (mutated parts are underlined)
- two types of PCR primers are used to encode 5'-GCACGATTCCTGCTCGAGGAACCTCTATG 1-3 '(rooster sequence No. 21) and its 5'-CATAGAGGTTCCTCGAGCAGGAATCG TGC-3' (SEQ ID NO: 22).
- the PCR method was performed on pGLDLIIP39-RcT (G145R) plasmid using 0u IckChange TM Site-Directed Mutagenesis Kit (Stratagene).
- thermostable DNA polymerase (Stratagene) was used as the thermostable DNA polymerase, and the PCR schedule was 95 ° C.
- HBsAg (Q129R, G145R) was identified by silver staining and Western method using anti-S monoclonal antibody (Funakoshi).
- HBsAg (Q129R, G145R) is a protein having a molecular weight of about 52 kDa.
- HBsAg purified HBsAg (Q129R, G145R) was obtained from the above cells (about 26 g) derived from 2.5 L of the culture medium. Particles were obtained.
- an Auszyme IIEIA kit (Dynabot), which can detect only the particle structure based on the S antigenicity of HBsAg, the HBsAg particles and HBsAg (Q129R, When the S antigenicity of the G145R) particles was measured, the former was 1 and the latter was less than 0.01.
- HBsAg (Q129R, G145R) particles have low antigen It has been clarified that the particles can be used as a stable and effective substance delivery method even in a living body using the particles. Industrial applicability
- the present invention provides new hollow nanoparticles used as carriers for transporting and introducing substances specifically to cells or tissues.
- these hollow nanoparticles retain a strong infection mechanism for specific cells or tissues, they do not have a viral genome, so they are highly safe and can be widely applied to gene therapy and DDS.
- it can be produced using a large-scale expression system, and has high industrial utility.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01902820A EP1262555B1 (en) | 2000-02-28 | 2001-02-09 | Protein hollow nano particles, transporter with the use of the same and method of introducing substance into cells |
US10/220,125 US7597905B2 (en) | 2000-02-28 | 2001-02-09 | Hollow protein nano-particles and method of introducing substances into cells |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-52525 | 2000-02-28 | ||
JP2000052525 | 2000-02-28 | ||
JP2001031308A JP4085231B2 (ja) | 2000-02-28 | 2001-02-07 | タンパク質中空ナノ粒子とそれを用いた物質運搬体、ならびに細胞への物質導入方法 |
JP2001-31308 | 2001-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001064930A1 true WO2001064930A1 (fr) | 2001-09-07 |
Family
ID=26586303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/000926 WO2001064930A1 (fr) | 2000-02-28 | 2001-02-09 | Nanoparticules creuses proteiques, transporteur associe a l'utilisation de ces nanoparticules et procede d'introduction d'une substance dans des cellules |
Country Status (5)
Country | Link |
---|---|
US (1) | US7597905B2 (ja) |
EP (1) | EP1262555B1 (ja) |
JP (1) | JP4085231B2 (ja) |
KR (1) | KR100645851B1 (ja) |
WO (1) | WO2001064930A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003082343A1 (fr) * | 2002-03-29 | 2003-10-09 | Japan Science And Technology Agency | Medicaments pour troubles hepatiques a base de nanoparticules proteiques creuses |
WO2003082330A1 (fr) * | 2002-03-29 | 2003-10-09 | Japan Science And Technology Agency | Medicament therapeutique comprenant des nanoparticules proteiques creuses presentant un anticorps et nanoparticules proteiques creuses |
WO2003082344A1 (fr) * | 2002-03-29 | 2003-10-09 | Japan Science And Technology Agency | Remedes a base de nanoparticules proteiques creuses renfermant un facteur de croissance ou analogue |
WO2003082345A1 (fr) * | 2002-03-29 | 2003-10-09 | Japan Science And Technology Agency | Medicaments comprenant des nanoparticules proteiques creuses et substance therapeutique destinee a etre a transferee dans des cellules avec lesquelles elles se fondent |
WO2004002459A1 (ja) * | 2002-06-28 | 2004-01-08 | Japan Science And Technology Agency | システイン残基を改変したタンパク質からなる中空ナノ粒子およびそれを用いた薬剤 |
WO2004082720A1 (ja) * | 2003-03-17 | 2004-09-30 | Beacle Inc. | 血友病治療用薬剤及びそれを用いた血友病治療方法 |
WO2008018555A1 (fr) * | 2006-08-11 | 2008-02-14 | National University Corporation Okayama University | PARTICULE HBsAg À FAIBLE ANTIGÉNICITÉ ET SON PROCÉDÉ DE PRODUCTION |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004175665A (ja) * | 2002-11-22 | 2004-06-24 | Japan Science & Technology Agency | タンパク質中空ナノ粒子およびそれを用いた薬剤 |
US8575110B2 (en) * | 2003-02-17 | 2013-11-05 | Alpha-O Peptides G | Peptidic nanoparticles as drug delivery and antigen display systems |
US8986736B2 (en) * | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
EP1663158A2 (en) * | 2003-06-24 | 2006-06-07 | Baxter International Inc. | Specific delivery of drugs to the brain |
BRPI0507308A (pt) * | 2004-01-29 | 2007-06-26 | Baxter Int | nanossuspensões de agentes anti-retrovirais para entrega ao sistema nervoso central aumentada |
WO2005095968A1 (ja) * | 2004-03-31 | 2005-10-13 | Toray Industries, Inc. | センシングツール |
BRPI0510271A (pt) * | 2004-06-15 | 2007-10-30 | Baxter Int | aplicações ex-vivo agentes terapêuticos microparticulados |
US7935517B2 (en) * | 2004-09-22 | 2011-05-03 | Nanolab, Inc. | Nanospearing for molecular transportation into cells |
WO2006116065A1 (en) * | 2005-04-21 | 2006-11-02 | The Trustees Of Boston College | Methods for molecular delivery into cells using nanotube spearing |
US20070059746A1 (en) * | 2005-09-14 | 2007-03-15 | Japan Science And Technology Agency | Substance carrier using hollow nanoparticle of hepatitis B virus protein and liposome, and method of introducing substance into cell |
JP2009120532A (ja) * | 2007-11-14 | 2009-06-04 | Osaka Univ | 糖及び糖鎖認識機構を利用する物質送達用及びバイオイメージング用バイオナノカプセル |
US9364443B2 (en) | 2008-03-05 | 2016-06-14 | Baxter International, Inc. | Compositions and methods for drug delivery |
US10952965B2 (en) * | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
JPWO2010137570A1 (ja) * | 2009-05-29 | 2012-11-15 | 学校法人慶應義塾 | 抗ウイルス剤または抗癌剤 |
WO2011133504A2 (en) * | 2010-04-20 | 2011-10-27 | University Of Florida Research Foundation, Inc. | Nanozymes, methods of making nanozymes, and methods of using nanozymes |
IN2014CN03364A (ja) | 2011-10-12 | 2015-09-04 | Alpha O Peptides Ag | |
JP6137894B2 (ja) * | 2013-03-22 | 2017-05-31 | 国立大学法人京都大学 | リポソーム−エキソソームハイブリッドベシクル及びその調製法 |
CN105713917A (zh) * | 2016-02-20 | 2016-06-29 | 深圳市圣必智科技开发有限公司 | 基于绿色荧光蛋白发光结构域标记的抗乙肝表面抗原抗体的制备方法 |
US20200061172A1 (en) | 2017-02-23 | 2020-02-27 | Alpha-O Peptides Ag | Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids |
WO2018172447A1 (en) | 2017-03-23 | 2018-09-27 | Alpha-O Peptides Ag | Self-assembling protein nanoparticles with built-in six-helix bundle proteins |
EP3607968A4 (en) | 2017-06-05 | 2021-03-31 | Beacle Inc. | VIRAL-TYPE PARTICLES INTENDED FOR USE TO INDUCE AN IMMUNE RESPONSE AGAINST HBV |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0201416A1 (fr) * | 1985-05-02 | 1986-11-12 | Institut Pasteur | Particules ayant les propriétés immunogènes de l'antigène HBs et portant un site antigénique étranger aux épitopes portés par l'antigène HBs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR732104A (fr) | 1932-02-16 | 1932-09-13 | Alfred Wiseman Ltd | Mécanisme de pompage perfectionné pour moteurs à combustion interne du type diesel ou à allumage par compression |
ZW18282A1 (en) | 1981-08-31 | 1983-03-23 | Genentech Inc | Preparation of polypeptides in vertebrate cell culture |
FR2560890B1 (fr) * | 1984-03-07 | 1987-10-16 | Grp Genie Genetique | Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention |
US5098704A (en) * | 1984-06-18 | 1992-03-24 | Chiron Corporation | Hepatitis surface antigen particle vaccine |
JPH10234383A (ja) * | 1997-02-28 | 1998-09-08 | Denka Seiken Co Ltd | E型肝炎ウイルス中空粒子、それをコードする遺伝子及びそれらの遺伝子を含む組換えベクターの作製方法と利用方法 |
AU7350798A (en) | 1997-04-29 | 1998-11-24 | Universiteit Utrecht | Corona virus-like particles as tools for vaccination and therapy |
US6797505B2 (en) | 1998-05-27 | 2004-09-28 | Cell Genesys, Inc. | Recombinant AAV vectors for gene therapy of hemophilia A |
US6740323B1 (en) * | 1999-11-24 | 2004-05-25 | Chiron Corporation | HBV/HCV virus-like particle |
-
2001
- 2001-02-07 JP JP2001031308A patent/JP4085231B2/ja not_active Expired - Lifetime
- 2001-02-09 EP EP01902820A patent/EP1262555B1/en not_active Expired - Lifetime
- 2001-02-09 US US10/220,125 patent/US7597905B2/en not_active Expired - Fee Related
- 2001-02-09 WO PCT/JP2001/000926 patent/WO2001064930A1/ja active IP Right Grant
- 2001-02-09 KR KR1020027011239A patent/KR100645851B1/ko not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0201416A1 (fr) * | 1985-05-02 | 1986-11-12 | Institut Pasteur | Particules ayant les propriétés immunogènes de l'antigène HBs et portant un site antigénique étranger aux épitopes portés par l'antigène HBs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes |
Non-Patent Citations (4)
Title |
---|
DELPEYROUX F. ET AL.: "Insertions in the hepatitis B surface antigen. Effect on assembly and secretion of 22-nm particles from mammalian cells", J. MOL. BIOL., vol. 195, no. 2, 1987, pages 343 - 350, XP002937463 * |
HANENBERG H. ET AL.: "Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells", NAT. MED., vol. 2, no. 8, 1996, pages 876 - 882, XP002937465 * |
KURODA S. ET AL.: "Hepatitis B virus envelope L protein particles. Synthesis and assembly in saccharomyces cerevisiae, purification and characterization", J. BIOL. CHEM., vol. 263, no. 3, 1992, pages 1953 - 1961, XP002937464 * |
PUMPENS P. ET AL.: "Hepatitis B core particles as a universal display model: A structure-function basis for development", FEBS LETT., vol. 442, no. 1, January 1999 (1999-01-01), pages 1 - 6, XP002937462 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003082343A1 (fr) * | 2002-03-29 | 2003-10-09 | Japan Science And Technology Agency | Medicaments pour troubles hepatiques a base de nanoparticules proteiques creuses |
WO2003082330A1 (fr) * | 2002-03-29 | 2003-10-09 | Japan Science And Technology Agency | Medicament therapeutique comprenant des nanoparticules proteiques creuses presentant un anticorps et nanoparticules proteiques creuses |
WO2003082344A1 (fr) * | 2002-03-29 | 2003-10-09 | Japan Science And Technology Agency | Remedes a base de nanoparticules proteiques creuses renfermant un facteur de croissance ou analogue |
WO2003082345A1 (fr) * | 2002-03-29 | 2003-10-09 | Japan Science And Technology Agency | Medicaments comprenant des nanoparticules proteiques creuses et substance therapeutique destinee a etre a transferee dans des cellules avec lesquelles elles se fondent |
US7951379B2 (en) | 2002-03-29 | 2011-05-31 | Japan Science And Technology Agency | Hollow nanoparticle of NBsAg large protein for drug delivery |
WO2004002459A1 (ja) * | 2002-06-28 | 2004-01-08 | Japan Science And Technology Agency | システイン残基を改変したタンパク質からなる中空ナノ粒子およびそれを用いた薬剤 |
EP1541135A1 (en) * | 2002-06-28 | 2005-06-15 | Japan Science and Technology Agency | Hollow nanoparticle having modified cysteine residue and drug with the use thereof |
EP1541135A4 (en) * | 2002-06-28 | 2005-09-28 | Japan Science & Tech Agency | HOLLOWING NANOTEILS WITH MODIFIED CYSTEIN REST AND MEDICAMENT WITH APPROPRIATE USE |
WO2004082720A1 (ja) * | 2003-03-17 | 2004-09-30 | Beacle Inc. | 血友病治療用薬剤及びそれを用いた血友病治療方法 |
WO2008018555A1 (fr) * | 2006-08-11 | 2008-02-14 | National University Corporation Okayama University | PARTICULE HBsAg À FAIBLE ANTIGÉNICITÉ ET SON PROCÉDÉ DE PRODUCTION |
JP5147697B2 (ja) * | 2006-08-11 | 2013-02-20 | 国立大学法人 岡山大学 | 低抗原性のHBsAg粒子及びその作製法 |
Also Published As
Publication number | Publication date |
---|---|
JP2001316298A (ja) | 2001-11-13 |
KR100645851B1 (ko) | 2006-11-14 |
EP1262555B1 (en) | 2011-09-14 |
US20030092069A1 (en) | 2003-05-15 |
JP4085231B2 (ja) | 2008-05-14 |
EP1262555A1 (en) | 2002-12-04 |
US7597905B2 (en) | 2009-10-06 |
KR20020092971A (ko) | 2002-12-12 |
EP1262555A4 (en) | 2008-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001064930A1 (fr) | Nanoparticules creuses proteiques, transporteur associe a l'utilisation de ces nanoparticules et procede d'introduction d'une substance dans des cellules | |
US20110052496A1 (en) | Hollow nanoparticles and uses thereof | |
US20090011036A1 (en) | Drug containing hollow protein nanoparticles of particle-forming protein, fused with disease-treating target-cell-substance | |
JP4212921B2 (ja) | 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子 | |
US20200215114A1 (en) | Compositions and methods for producing exosome loaded therapeutics for the treatment of multiple oncological disorders | |
KR100674325B1 (ko) | 단백질 중공 나노 입자 및 이를 이용한 약제 | |
WO2004002459A1 (ja) | システイン残基を改変したタンパク質からなる中空ナノ粒子およびそれを用いた薬剤 | |
EP1491215A1 (en) | Remedies with the use of hollow protein nanoparticles presenting growth factor or the like | |
WO2004082720A1 (ja) | 血友病治療用薬剤及びそれを用いた血友病治療方法 | |
WO2003082343A1 (fr) | Medicaments pour troubles hepatiques a base de nanoparticules proteiques creuses | |
CN118147179A (zh) | 一种治疗肝癌用核酸分子、融合蛋白及mRNA疫苗 | |
JP2005517405A (ja) | 増殖性疾患の遺伝子療法的治療のための微生物 | |
CN117721129A (zh) | 能高效表达目的基因的mRNA载体系统、其构建及应用 | |
WO2005049824A1 (ja) | 生体構造認識部位を提示する中空ナノ粒子およびその生産方法、並びにその利用 | |
Chang et al. | Section Review Anti-infectives: Recent advances in anti-hepatitis B virus agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020027011239 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001902820 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10220125 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001902820 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027011239 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020027011239 Country of ref document: KR |